CytomX stock soars to 52-week high, hits $2.66

CytomX Therapeutics Inc (NASDAQ:CTMX). shares have reached a new 52-week high, touching $2.66 and signaling a robust period for the biopharmaceutical company. According to InvestingPro data, the stock appears fairly valued at current levels, with impressive gains of 137% over the past six months and a market capitalization of $413 million. This milestone reflects a significant turnaround, with the stock witnessing an impressive 54.41% increase over the past year. While investors have shown increased confidence in CytomX’s potential, driven by promising developments in its pipeline of cancer treatments and strategic partnerships, InvestingPro analysis indicates the stock is currently in overbought territory, with 5 analysts recently revising their earnings expectations downward. The company maintains strong fundamentals with a healthy current ratio of 1.73 and more cash than debt on its balance sheet. The company’s progress in advancing novel therapies has been a key factor in the stock’s performance, as market participants continue to monitor its growth trajectory and future prospects in the competitive biotech landscape. With a P/E ratio of 5.16 and analyst price targets ranging from $3.50 to $8.00, investors seeking deeper insights can access 15 additional ProTips and comprehensive analysis through InvestingPro’s detailed research reports.

In other recent news, CytomX Therapeutics reported impressive financial results for the first quarter of 2025, significantly exceeding earnings and revenue expectations. The company posted an earnings per share (EPS) of $0.27, compared to the forecasted $0.06, and achieved revenue of $50.92 million, surpassing the anticipated $29.7 million. Additionally, CytomX announced the initiation of a Phase 1 clinical trial for its new cancer treatment, CX-801, in combination with Merck (NSE:PROR)’s KEYTRUDA® for metastatic melanoma. The trial follows successful early dose escalation studies of CX-801 as a monotherapy. Moreover, H.C. Wainwright upgraded CytomX stock from Neutral to Buy, setting a new price target of $5.00, driven by promising clinical data for its EpCAM ProBody Topo-1 ADC, CX-2051, in colorectal cancer. The highest dose of 10 mg/kg in the study showed a confirmed response rate of 43% in patients. CytomX plans to expand enrollment at each dose level to gather more substantial data. These developments reflect the company’s strategic focus on advancing its oncology pipeline and have been well-received by investors and analysts alike.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.